JP2024526849A5 - - Google Patents
Info
- Publication number
- JP2024526849A5 JP2024526849A5 JP2024503400A JP2024503400A JP2024526849A5 JP 2024526849 A5 JP2024526849 A5 JP 2024526849A5 JP 2024503400 A JP2024503400 A JP 2024503400A JP 2024503400 A JP2024503400 A JP 2024503400A JP 2024526849 A5 JP2024526849 A5 JP 2024526849A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- compound according
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223788P | 2021-07-20 | 2021-07-20 | |
| US63/223,788 | 2021-07-20 | ||
| PCT/US2022/037756 WO2023003973A1 (en) | 2021-07-20 | 2022-07-20 | Inhibitors targeting ubiquitin specific protease 7 (usp7) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526849A JP2024526849A (ja) | 2024-07-19 |
| JP2024526849A5 true JP2024526849A5 (cg-RX-API-DMAC7.html) | 2025-06-27 |
Family
ID=82899138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503400A Pending JP2024526849A (ja) | 2021-07-20 | 2022-07-20 | ユビキチン特異的プロテアーゼ7(usp7)を標的とする阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240376076A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4373816A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024526849A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118401507A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022315201A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3225596A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023003973A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018342089B2 (en) | 2017-09-26 | 2024-07-11 | Dana-Farber Cancer Institute, Inc. | Novel USP7 inhibitors for treating multiple myeloma |
| EP3870179A4 (en) | 2018-10-22 | 2022-11-23 | Dana Farber Cancer Institute, Inc. | USP7 ESCAPEMENT |
| US20240150362A1 (en) | 2022-08-25 | 2024-05-09 | Molecure S.A. | Substituted Pyrrolotriazines |
| CN121135717A (zh) * | 2024-06-14 | 2025-12-16 | 中国科学院上海药物研究所 | 一种靶向泛素化降解usp7蛋白的化合物、其药物组合物和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI698436B (zh) * | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
| MA41291A (fr) * | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| AU2018342089B2 (en) * | 2017-09-26 | 2024-07-11 | Dana-Farber Cancer Institute, Inc. | Novel USP7 inhibitors for treating multiple myeloma |
| EP3870179A4 (en) * | 2018-10-22 | 2022-11-23 | Dana Farber Cancer Institute, Inc. | USP7 ESCAPEMENT |
-
2022
- 2022-07-20 JP JP2024503400A patent/JP2024526849A/ja active Pending
- 2022-07-20 EP EP22754635.5A patent/EP4373816A1/en active Pending
- 2022-07-20 CA CA3225596A patent/CA3225596A1/en active Pending
- 2022-07-20 US US18/580,725 patent/US20240376076A1/en active Pending
- 2022-07-20 AU AU2022315201A patent/AU2022315201A1/en not_active Abandoned
- 2022-07-20 WO PCT/US2022/037756 patent/WO2023003973A1/en not_active Ceased
- 2022-07-20 CN CN202280051554.7A patent/CN118401507A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7536064B2 (ja) | 抗癌活性及び抗増殖活性を呈する2-アミノピリミジン-6-オン及び類似体 | |
| CA3114240C (en) | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors | |
| AU2018362046B2 (en) | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation | |
| CN104903334B (zh) | 一种替诺福韦前药及其在医药上的应用 | |
| JP6474068B2 (ja) | 2−アミノピリミジン系化合物およびその薬物組成物と使用 | |
| JP2022527114A5 (cg-RX-API-DMAC7.html) | ||
| JP2021529814A (ja) | 化学化合物 | |
| JP2020522553A (ja) | Atf4経路阻害剤としての化合物 | |
| JP2021527098A (ja) | 縮合チオフェン化合物 | |
| JP2016505586A5 (cg-RX-API-DMAC7.html) | ||
| BR112020000086A2 (pt) | derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças | |
| PT2344449E (pt) | Compostos de aril-fenil-sulfonamido-cicloalquilo e sua utilização | |
| JP2010511013A5 (cg-RX-API-DMAC7.html) | ||
| JPH06500117A (ja) | 抗腫瘍活性を増強させる2,4−ジアミノキナゾリン誘導体 | |
| JP2010509285A5 (cg-RX-API-DMAC7.html) | ||
| JP2008504304A5 (cg-RX-API-DMAC7.html) | ||
| TW201014865A (en) | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | |
| JP2023512557A5 (cg-RX-API-DMAC7.html) | ||
| EP3924341A1 (en) | Compounds, compositions and methods | |
| JP2006509842A5 (cg-RX-API-DMAC7.html) | ||
| CA3214808A1 (en) | Thienopyrrole compounds | |
| JP6192613B2 (ja) | ニトリル誘導体ならびにそれらの薬学的使用および組成物 | |
| JP2017501215A (ja) | ブロモドメイン阻害剤としてのキノリン誘導体 | |
| JP2022503821A5 (cg-RX-API-DMAC7.html) | ||
| JP2019528300A (ja) | インドールアミン2,3−ジオキシゲナーゼの阻害剤およびその使用方法 |